Phase I/II Study of Oral ONC201 in Patients With Relapsed/Refractory Non-Hodgkin's Lymphoma

Trial Profile

Phase I/II Study of Oral ONC201 in Patients With Relapsed/Refractory Non-Hodgkin's Lymphoma

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 31 Mar 2017

At a glance

  • Drugs ONC 201 (Primary)
  • Indications Non-Hodgkin's lymphoma
  • Focus Adverse reactions
  • Most Recent Events

    • 28 Mar 2017 Status changed from active, no longer recruiting to recruiting.
    • 22 Nov 2016 Status changed from recruiting to active, no longer recruiting.
    • 18 Nov 2016 Planned number of patients changed from 150 to 60.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top